BSX vs EW
Boston Scientific and Edwards Lifesciences, both Healthcare
Boston Scientific is the larger company at $67B against $50B. On trailing earnings BSX is the cheaper of the two at a P/E of 17.3 against 49.0, a gap that is only a bargain if the two are growing at similar rates. Over the past year EW returned +14% against -56% for BSX. The RyuScore puts BSX ahead, 65 against 60 out of 100.
| Figure | BSX | EW |
|---|---|---|
| Last close | $42.74 | $85.20 |
| Market cap | $67B | $50B |
| Trailing P/Elower is cheaper for the same earnings, not automatically better | 17.3 | 49.0 |
| 1-year return | -56% | +14% |
| 5-year return | -3.3% | -29% |
| RyuScoresector-relative, 1–10 | 65/100 | 60/100 |
Figures from SEC filings and end-of-day closes. Highlighting marks the higher or lower number, which is not the same as the better investment, a low P/E can be a warning and a high one can be deserved.
Boston Scientific
Revenue of $5.4B in Q2 2026, net income $905M. Its largest reported line is Electrophysiology EP, 18% of the disclosed total.
Edwards Lifesciences
Revenue of $1.7B in Q2 2026, net income $241M. Its largest reported line is Transcatheter Aortic Valve Replacement, 72% of the disclosed total.
Open these two in the interactive comparison to add more names, change the period or see the correlation.